Methyl 2,5-Dihydroxybenzoate
CAS 2150-46-1
Methyl 2,5-Dihydroxybenzoate (CAS 2150-46-1) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 99870.01490566038 nM | 53 | - |
| - | Ki | 2060 nM | 6 | - |
| - | IC50 | 98020 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Methyl 2,5-Dihydroxybenzoate used for in pharmaceutical contexts?
Methyl 2,5-Dihydroxybenzoate (CAS 2150-46-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Methyl 2,5-Dihydroxybenzoate?
No adverse-event association or SIDER side-effect rows are rendered for Methyl 2,5-Dihydroxybenzoate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Methyl 2,5-Dihydroxybenzoate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Methyl Gentisate with EU status "prohibited".
What clinical phase is Methyl 2,5-Dihydroxybenzoate in?
No phase 1-4 clinical development badge is rendered for Methyl 2,5-Dihydroxybenzoate because the matched compound identifier rows do not contain a max-phase value.